2016/04/15
Munich, Germany, April 15, 2016-WuXi AppTec, a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that it has acquired Crelux GmbH, a leading structure based drug discovery provider based in Munich, Germany. The addition of Crelux provides augmented scientific depth and complements existing capabilities within the WuXi structure-based drug discovery platform.
Read more2016/04/11
Shanghai, April 11, 2016 – WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, today announced that WuXi Lab Testing Division (LTD)’s late-and commercial-stage analytical and stability testing facilities in Shanghai successfully passed an FDA inspection for GMP compliance.
Read more2016/04/08
SEATTLE and SHANGHAI– April 8, 2016 – Juno Therapeutics (NASDAQ: JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, and WuXi AppTec, a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that they have started a new company in China.
Read more2016/03/25
Seoul, March 25, 2016 – WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, today announced the opening of its branch office in Seoul, South Korea, one of the most dynamic life science innovation hubs in the Asia Pacific region.
Read more2016/03/04
SHANGHAI, March 4, 2016 /PRNewswire/ -- WuXi AppTec Co. Ltd. (WuXi), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that its small-molecule process development and manufacturing subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd. (STA) began operations ata new, fully integrated R&D and cGMP manufacturing site in Changzhou in February 2016.
Read more